<DOC>
	<DOCNO>NCT01028027</DOCNO>
	<brief_summary>This study evaluate safety efficacy loteprednol etabonate [ LE ] tobramycin ophthalmic suspension versus tobramycin dexamethasone ophthalmic suspension treatment ocular inflammation associate blepharokeratoconjunctivitis ( BKC ) .</brief_summary>
	<brief_title>Loteprednol Tobramycin Versus Tobramycin Dexamethasone , Treatment Blepharokeratoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Blepharitis</mesh_term>
	<mesh_term>Keratitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Subjects must clinical diagnosis BKC least one eye Subjects must willing discontinue contact lens use duration study Subjects able willing comply treatment follow up/study procedure . Subjects participate drug device clinical investigation within 30 day prior entry study and/or period study participation . Subjects uncontrolled systemic disease debilitate disease . Subjects know hypersensitivity study drug component ( include benzalkonium chloride ) contraindication tobramycin ocular corticosteroid . Subjects use topical systemic ophthalmic medication list disallow study protocol , within specify time frame prior Visit 1 . Subjects disease condition Investigator determines could interfere safety efficacy evaluation study drug . Subjects ocular surgery ( include laser surgery ) either eye within past three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Blepharokeratoconjunctivitis</keyword>
</DOC>